Experimental CAR-T therapy targets tough blood cancers in tiny early trial
NCT ID NCT05895994
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new cell therapy called RD13-02 in just 2 people with relapsed or refractory CD7-positive blood cancers (like T-cell leukemia or lymphoma). The treatment uses specially engineered immune cells to attack cancer cells. The main goals were to check safety and see how the cells behave in the body. Because it is so small and early, we cannot draw any firm conclusions yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RD13-02 CAR-T cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for certain hard-to-treat blood cancers.
What could go wrong
This is a very early, tiny study (only 2 people). It is too small to know if the treatment is safe or effective. Many early-stage therapies do not pan out.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China